R C Hubbard

Summary

Affiliation: Pharmacia Corporation
Country: USA

Publications

  1. ncbi Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia
    R C Hubbard
    Pharmacia, 5200 Old Orchard Road, Skokie, IL 60077, USA
    Br J Anaesth 90:166-72. 2003
  2. ncbi Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis
    A Karim
    Searle Research and Development, Skokie, Illinois 60077, USA
    J Rheumatol 26:2539-43. 1999
  3. ncbi A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects
    A Karim
    Pharmacia Research and Development, Skokie, Illinois 60077, USA
    J Clin Pharmacol 41:1111-9. 2001
  4. ncbi A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model
    S E Daniels
    SCIREX Corporation, Austin, Texas, USA
    Clin Ther 23:1018-31. 2001
  5. ncbi The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively
    P J Desjardins
    SCIREX Corporation, Austin, Texas, USA
    Anesth Analg 93:721-7. 2001
  6. ncbi Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
    S I Harris
    SeaView Research, Miami, Florida, USA
    Clin Ther 23:1422-8. 2001
  7. ncbi The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain
    D R Mehlisch
    SCIREX, Austin, Texas, USA
    J Am Dent Assoc 135:1578-90. 2004
  8. ncbi Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee
    G W Williams
    Division of Rheumatology, Scripps Clinic, La Jolla, California, USA
    Clin Ther 23:213-27. 2001
  9. ncbi Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
    J L Goldstein
    Section of Digestive and Liver Diseases, University of Illinois at Chicago, 60612-7323, USA
    Am J Gastroenterol 96:1019-27. 2001

Collaborators

Detail Information

Publications9

  1. ncbi Parecoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia
    R C Hubbard
    Pharmacia, 5200 Old Orchard Road, Skokie, IL 60077, USA
    Br J Anaesth 90:166-72. 2003
    ..This multicentre, double-blind, placebo-controlled study compared the opioid-sparing effectiveness and clinical safety of parecoxib sodium over 48 h, in 195 postoperative patients after routine total knee replacement surgery...
  2. ncbi Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis
    A Karim
    Searle Research and Development, Skokie, Illinois 60077, USA
    J Rheumatol 26:2539-43. 1999
    ..To determine the effects of celecoxib, a specific inhibitor of cyclooxygenase 2 (COX-2) on the renal clearance and plasma pharmacokinetic profile of stable methotrexate (MTX) doses in patients with rheumatoid arthritis (RA)...
  3. ncbi A pharmacokinetic study of intramuscular (i.m.) parecoxib sodium in normal subjects
    A Karim
    Pharmacia Research and Development, Skokie, Illinois 60077, USA
    J Clin Pharmacol 41:1111-9. 2001
    ..All single i.m. doses up to the maximum of 40 mg of parecoxib, as well as concentrations of up to 20 mg/ml, were well tolerated...
  4. ncbi A double-blind, randomized comparison of intramuscularly and intravenously administered parecoxib sodium versus ketorolac and placebo in a post-oral surgery pain model
    S E Daniels
    SCIREX Corporation, Austin, Texas, USA
    Clin Ther 23:1018-31. 2001
    ..05). All treatments were well tolerated. CONCLUSIONS: Parecoxib IV and IM provided effective analgesia. The 40-mg dose was comparable to ketorolac 60 mg on most measures of analgesia but had a longer duration of action...
  5. ncbi The injectable cyclooxygenase-2-specific inhibitor parecoxib sodium has analgesic efficacy when administered preoperatively
    P J Desjardins
    SCIREX Corporation, Austin, Texas, USA
    Anesth Analg 93:721-7. 2001
    ..These findings suggest that preoperative administration of parecoxib sodium, the injectable prodrug of the cyclooxygenase-2 specific inhibitor valdecoxib, is effective, safe, and well tolerated for treating postoperative pain...
  6. ncbi Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
    S I Harris
    SeaView Research, Miami, Florida, USA
    Clin Ther 23:1422-8. 2001
    ..CONCLUSION: These findings suggest that elderly patients may be at risk for GI ulceration even after short-term use of the conventional NSAIDs ketorolac and naproxen...
  7. ncbi The analgesic efficacy of intramuscular parecoxib sodium in postoperative dental pain
    D R Mehlisch
    SCIREX, Austin, Texas, USA
    J Am Dent Assoc 135:1578-90. 2004
    ..m. after dental surgery. It also is well-tolerated. CLINICAL IMPLICATIONS: These findings support the use of parecoxib 20 mg i.m. as an initial dosing option for postoperative pain management in countries in which it is approved...
  8. ncbi Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee
    G W Williams
    Division of Rheumatology, Scripps Clinic, La Jolla, California, USA
    Clin Ther 23:213-27. 2001
    ..The availability of 2 effective regimens provides patients and physicians with increased flexibility in the selection of an appropriate dosing regimen for celecoxib therapy...
  9. ncbi Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
    J L Goldstein
    Section of Digestive and Liver Diseases, University of Illinois at Chicago, 60612-7323, USA
    Am J Gastroenterol 96:1019-27. 2001
    ....